These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30100060)

  • 1. Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway.
    Yang Z; Tao Y; Xu X; Cai F; Yu Y; Ma L
    Biochem Biophys Res Commun; 2018 Sep; 503(3):2124-2131. PubMed ID: 30100060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway.
    Gai JQ; Sheng X; Qin JM; Sun K; Zhao W; Ni L
    Int J Oncol; 2016 Jan; 48(1):338-48. PubMed ID: 26648168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways.
    Chen YY; Lu HF; Hsu SC; Kuo CL; Chang SJ; Lin JJ; Wu PP; Liu JY; Lee CH; Chung JG; Chang JB
    Environ Toxicol; 2015 Jan; 30(1):74-82. PubMed ID: 23949904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells.
    Qiu DZ; Zhang ZJ; Wu WZ; Yang YK
    BMC Complement Altern Med; 2013 Jul; 13():185. PubMed ID: 23870199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin.
    Sheng X; Zhu P; Zhao Y; Zhang J; Li H; Zhao H; Qin J
    Recent Pat Anticancer Drug Discov; 2021; 16(1):54-65. PubMed ID: 33530915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice.
    Zhang ZJ; Yang YK; Wu WZ
    J Transl Med; 2014 Feb; 12():57. PubMed ID: 24581171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
    Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
    Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
    Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
    Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells.
    Tsai SC; Yang JS; Peng SF; Lu CC; Chiang JH; Chung JG; Lin MW; Lin JK; Amagaya S; Wai-Shan Chung C; Tung TT; Huang WW; Tseng MT
    Int J Oncol; 2012 Oct; 41(4):1431-42. PubMed ID: 22858649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calenduloside E inhibits hepatocellular carcinoma cell proliferation and migration by down-regulating GPX4 and SLC7A11 expression through the autophagy pathway].
    Chen Q; Shang S; Lu H; Li S; Sun Z; Fan X; Qi Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jul; 44(7):1327-1335. PubMed ID: 39051078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway.
    Li D; Zhang B; Hu C
    Acta Biochim Biophys Sin (Shanghai); 2017 Jul; 49(7):581-587. PubMed ID: 28475688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma.
    Zhang Z; Yan Z; Yuan Z; Sun Y; He H; Mai C
    Tumour Biol; 2015 Mar; 36(3):1503-9. PubMed ID: 25537088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin.
    Sheng X; Zhu P; Qin J; Li Q
    Oncol Rep; 2018 Jun; 39(6):2931-2941. PubMed ID: 29658591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase.
    Yu Z; Feng H; Sun X; Zhuo Y; Li M; Zhou Z; Huang L; Jiang Y; Zhu X; Zhang X; Le F; Zheng C; Cheng AS; Gao Y
    Sci Rep; 2018 Mar; 8(1):3891. PubMed ID: 29497076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-related hepatocellular carcinoma.
    Yang Z; Zhuang L; Yu Y; Zhou W; Lu Y; Xu Q; Tang B; Chen X
    Discov Med; 2015 Dec; 20(112):349-56. PubMed ID: 26760979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells.
    Hsu CM; Tsai Y; Wan L; Tsai FJ
    Int J Oncol; 2013 Jul; 43(1):338-48. PubMed ID: 23677253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
    Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
    Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Li Z; Yang J; Sun Y; Han S; Gong J; Zhang Y; Feng Z; Yao H; Shi P
    Drug Des Devel Ther; 2024; 18():2745-2760. PubMed ID: 38974120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.